FMR LLC discloses 9.2% stake in Eikon Therapeutics
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
FMR LLC and Abigail P. Johnson report a significant ownership position in Eikon Therapeutics Inc. common stock on an amended Schedule 13G. FMR LLC beneficially owns 4,993,906 shares of common stock, representing 9.2% of the outstanding class.
FMR LLC has sole voting power over 4,992,603 shares and sole dispositive power over 4,993,906 shares, with no shared voting or dispositive power. Abigail P. Johnson reports sole dispositive power over the same 4,993,906 shares, but no voting power. One or more other persons may receive dividends or sale proceeds related to these shares, but no other person holds an interest exceeding five percent of the class.
Key Figures
Key Terms
beneficially owned financial
sole voting power financial
sole dispositive power financial
Schedule 13G regulatory
parent holding company financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in EIKN does FMR LLC report on this Schedule 13G/A?
Does any other investor besides FMR LLC hold over 5% of EIKN through this position?
What class of EIKN securities is covered by this Schedule 13G/A filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.